Trader Note — 9349 total
XLC, the Communication Services Select Sector SPDR ETF, enters June with short sellers meaningfully pulling back — just as the price itself wobbles and AT&T, one of its top holdings, slides on fresh selling…
KKR enters the first week of June with a curious split: every insider who bought the stock near these levels in February and March is sitting on a small loss, yet short sellers are only just beginning to show up in any…
Construction Partners enters June with fresh analyst coverage and a stock under pressure — a combination that sets up an interesting read on where conviction actually sits. The week's standout event arrived this…
Bit Digital dropped 6% on Tuesday to close at $1.98, giving back gains after a month that still delivered a 26% return. The week's tension is straightforward: a persistent short position near its six-week high is…
AVGO delivered its Q2 earnings on June 3 and the market's verdict was swift — the stock closed at $481.57, up 4.7% on the day and 14% on the week, breaking cleanly above the analyst target cluster that had been framing…
Arcus Biosciences enters the stretch before its June 11 earnings report carrying two conflicting signals: a fresh clinical collaboration with Bristol Myers Squibb that validates its HIF-2α inhibitor, casdatifan, and a…
Solid Biosciences heads into its June 10 earnings report with an unusual split: short interest climbing while the Street grows more bullish. The earnings event is the lens through which everything else reads this week.…
Vir Biotechnology heads into the first week of June with a deteriorating price chart, rising short interest, and one bullish analyst move that hasn't stopped the stock from falling — a gap worth examining closely. The…
SMPL heads into its next earnings print with short sellers at their most aggressive in months, analyst conviction evaporating, and options traders positioned firmly for further pain. The shift in short positioning is…
Celcuity enters the week after one of its sharpest single-week drops in recent memory — down 32% in five sessions and 26% on Tuesday alone, closing at $91.42. The move puts the stock more than 37% below its one-month…
Ingersoll Rand heads into its June 11 earnings release with analyst conviction fading, short interest climbing, and the stock down 8% in a month — a setup that puts real pressure on the print to stabilise the…
UroGen Pharma heads into its June 22 earnings report with a stock that has lost nearly 10% on the week — yet short sellers have been quietly covering rather than pressing their bets. The week's central tension is that…
Zymeworks enters June with a growing gap between where analysts think it should trade and where it actually is — a widening that has become the defining tension of the past month. The stock closed at $24.11 on June 2,…
VBNK delivered its Q2 2026 results this morning with a beat on revenue and an inline EPS print — but the numbers arrived against a backdrop of a quietly building short position and a cost-to-borrow that more than…
Fortive Corporation enters its June 9 earnings call with short sellers steadily unwinding positions — but the analyst community remains cautious, and options traders are nowhere near as defensive as they were just…
Willis Towers Watson enters June with a striking split personality: short sellers have been aggressively rebuilding positions since April's earnings collapse, while the CEO and a divisional president stepped in with…
Axsome Therapeutics heads into its Q1 2026 earnings call on Friday, June 5 carrying two competing signals: a freshly settled SUNOSI patent dispute that removes a meaningful overhang, and a persistent pattern of insider…
XLRE heads into June with an unusual combination: short sellers rebuilding positions at pace while the borrowing cost to fund those trades actually falls. The most striking development this week is the scale of short…
Madison Square Garden Sports Corp. heads into June with a striking split: short sellers have meaningfully rebuilt positions over the past week, yet options traders are the most bullish they have been all year. The…
CytomX Therapeutics enters a pivotal week with a headline-grabbing Regeneron collaboration pulling in one direction and a 14% stock decline pulling hard in the other. CytomX announced an expansion of its strategic…
